Cart
sales@molnova.com
Home - Products - Others - Other Targets - RMC-6291

RMC-6291

CAS No. 2641998-63-0

RMC-6291( —— )

Catalog No. M36627 CAS No. 2641998-63-0

RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 613 In Stock
5MG 306 In Stock
10MG 550 In Stock
25MG 1121 In Stock
50MG 1814 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    RMC-6291
  • Note
    Research use only, not for human use.
  • Brief Description
    RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models .
  • Description
    RMC-6291 is an orally active and covalent inhibitor of KRASG12C(ON). RMC-6291 forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). Thus, RMC-6291 prevents KRASG12C(ON) from signaling via steric blockade of RAS effector binding. RMC-6291 elicits deep and durable suppression on RAS pathway activity in KRASG12C tumor models.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Kras
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2641998-63-0
  • Formula Weight
    1012.26
  • Molecular Formula
    C55H78FN9O8
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (98.79 mM; Ultrasonic )
  • SMILES
    O=C(C#CC(N(C)C)(C)C)N1CCC(F)(C(=O)N(C)C(C(=O)NC2C(=O)N3NC(C(=O)OCC(C)(C)CC=4C5=CC(=CC=C5N(C4C=6C=CC=NC6C(OC)C)CC)N7CCOC(C7)C2)CCC3)C(C)C)CC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Nichols R J, et al. RMC-6291, a next-generation tri-complex KRASG12C (ON) inhibitor, outperforms KRASG12C (OFF) inhibitors in preclinical models of KRASG12C cancers[J]. Cancer Research, 2022, 82(12_Supplement): 3595-3595.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • 3,8-Di-O-methylellag...

    3,3'-Di-O-methylellagic acid reveals moderate antibacterial activity, it also shows strong DPPH radical scavenging activities with SC50 of 123.3 ug/mL.

  • Ligustilide

    Ligustilide is an effective constituent extracted from Angelica sinensis.

  • Luteolin 7-rutinosid...

    Luteolin-7-rutinoside has both antifungal activities and anti-arthritic, can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection.

Sign In Join Free